Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 16/20 | 0.55 |
| ▸ | METAP1 | P53582 | 8/20 | 0.55 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7328407 | 1.00 | METAP2 (0.55) | METAP2METAP1REN | |
| Hydrochloric Acid SCHEMBL9514516 | 0.98 | METAP2 (0.53) | METAP2METAP1REN | |
| Hydrochloric Acid SCHEMBL9514519 | 0.98 | METAP2 (0.53) | METAP2METAP1REN | |
| SCHEMBL8209396 | 0.95 | METAP2 (0.49) | METAP2METAP1REN | |
| SCHEMBL13347345 | 0.95 | METAP2 (0.49) | METAP2METAP1REN | |
| SCHEMBL8202433 | 0.95 | METAP2 (0.49) | METAP2METAP1REN | |
| SCHEMBL13430909 | 0.91 | METAP2 (0.45) | METAP2METAP1REN | |
| SCHEMBL10138824 | 0.91 | METAP2 (0.45) | METAP2METAP1REN | |
| Trifluoroacetic Acid SCHEMBL7327225 | 0.90 | METAP2 (0.50) | METAP2METAP1REN | |
| Hydrochloric Acid SCHEMBL27076653 | 0.90 | METAP2 (0.44) | METAP2METAP1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293915-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2012-10-23 | — | — | US | disclosed |
| US-8293915-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2012-10-23 | — | — | US | disclosed |
| US-20100056756-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| US-20100056756-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| WO-2008097676-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2008-08-14 | — | — | WO | disclosed |
| US-4904660-A | HYPOTENSIVE AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1990-02-27 | — | — | US | disclosed |
| EP-0281316-A2 | Renin inhibitors | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056756-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS1, PRSS8, PRSS2 | METAP2 124/4885METAP1 142/4885REN 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.